AC
REGN icon

Abbrea Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Abbrea Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$266K Sell
253
-15
-6% -$14.5K 0.04% 200
2024
Q1 		$258K Hold
268
– – 0.03% 223
2023
Q4 		$235K Buy
+268
New +$221K 0.03% 222

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Abbrea Capital's REGN Position: Q2 2024 in Review

Abbrea Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 5.6% in Q2 2024, selling an estimated $14.5K and leaving 253 shares worth $266K. The position accounts for 0.04% of the portfolio, ranked #200.

Abbrea Capital first reported a position in REGN in Q4 2023 and has held it in 3 quarters since. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Abbrea Capital held 253 shares of Regeneron Pharmaceuticals worth $266K as of Q2 2024.
  • Abbrea Capital sold 15 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $14.5K.
  • Regeneron Pharmaceuticals made up 0.04% of Abbrea Capital's portfolio in Q2 2024, its #200 holding.
  • Abbrea Capital first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • 1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.